Three patients have been treated with low dose of TC-A101 without cytokine release syndrome manifestation or any other CAR-T related adverse events. We observed objective tumor regression in two of these three patients, with one patient reaching the threshold of partial response....The preclinical and initial clinical findings reported here indicate that TC-A101 T cell immunotherapy is safe and potentially efficacious against female reproductive cancers expressing ALPP.